Cargando…

Exenatide: A New Promising Antidiabetic Agent

Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the d...

Descripción completa

Detalles Bibliográficos
Autor principal: Chakraborti, C. K.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883206/
https://www.ncbi.nlm.nih.gov/pubmed/20582183
http://dx.doi.org/10.4103/0250-474X.62228
_version_ 1782182242856992768
author Chakraborti, C. K.
author_facet Chakraborti, C. K.
author_sort Chakraborti, C. K.
collection PubMed
description Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the destruction of islet beta-cells, type 2 diabetes mellitus patients are not rapidly converted to type 1 diabetes mellitus and ultimately appearance of complications of the disease is halted or delayed. Its long-acting-release formula, which would be used once per week, simultaneously retaining all the properties of twice-daily subcutaneous administration, is undergoing clinical trial. This drug is considered as an adjunct to metformin/sulfonylureas/insulin.
format Text
id pubmed-2883206
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-28832062010-06-25 Exenatide: A New Promising Antidiabetic Agent Chakraborti, C. K. Indian J Pharm Sci Review Article Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the destruction of islet beta-cells, type 2 diabetes mellitus patients are not rapidly converted to type 1 diabetes mellitus and ultimately appearance of complications of the disease is halted or delayed. Its long-acting-release formula, which would be used once per week, simultaneously retaining all the properties of twice-daily subcutaneous administration, is undergoing clinical trial. This drug is considered as an adjunct to metformin/sulfonylureas/insulin. Medknow Publications 2010 /pmc/articles/PMC2883206/ /pubmed/20582183 http://dx.doi.org/10.4103/0250-474X.62228 Text en © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Chakraborti, C. K.
Exenatide: A New Promising Antidiabetic Agent
title Exenatide: A New Promising Antidiabetic Agent
title_full Exenatide: A New Promising Antidiabetic Agent
title_fullStr Exenatide: A New Promising Antidiabetic Agent
title_full_unstemmed Exenatide: A New Promising Antidiabetic Agent
title_short Exenatide: A New Promising Antidiabetic Agent
title_sort exenatide: a new promising antidiabetic agent
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883206/
https://www.ncbi.nlm.nih.gov/pubmed/20582183
http://dx.doi.org/10.4103/0250-474X.62228
work_keys_str_mv AT chakrabortick exenatideanewpromisingantidiabeticagent